Nigeria received its first consignment of lenacapavir, a twice-yearly injectable HIV prevention drug that clinical trials showed prevents infection in nearly all cases, on 10 March 2026, marking the arrival of one of the most significant advances in HIV prevention since the introduction of oral pre-exposure prophylaxis — but health analysts and advocates have moved quickly to flag that the drug’s arrival in the country and its actual delivery to the clinics and communities where it is most needed are two entirely different milestones, with the second far from guaranteed. Lenacapavir, developed by Gilead Sciences as a capsid inhibitor and administered by subcutaneous injection every six months, demonstrated 100 per cent efficacy in the PURPOSE 1 trial among cisgender women in Uganda and South Africa and a 96 per cent reduction in HIV incidence among men, transgender and non-binary individuals in the PURPOSE 2 trial. The World Health Organisation formally recommended it in July 2025. Nigeria received regulatory approval from NAFDAC, completed readiness assessments in ten states — including Lagos, Kano, Akwa Ibom, Anambra and the FCT — and conducted national and state-level training for healthcare workers in preparation for a phased rollout.
The gap between arrival and access has already become visible in the pattern of the global rollout. Countries that launched earlier, including Kenya in February 2026 and South Africa in early 2026, have shown that integrating lenacapavir into public health systems requires deliberate community engagement, trained personnel willing to administer the injection, patients comfortable presenting at clinics where HIV stigma remains significant, and a functioning cold chain and supply logistics that can serve rural and peri-urban areas where the epidemic burden is often highest. In Nigeria, the picture is further complicated by the closure of five key population clinics in the South-South region due to donor funding instability, cutting off approximately 800 people from antiretrovirals, PrEP and related services. Nigeria accounts for one of the largest HIV epidemics globally, with hundreds of thousands of new infections annually, and the populations most at risk — young women, key populations in underserved regions — are the ones least likely to be reached by a rollout that concentrates initially on urban centres with established clinic networks.
The question of sustainability is also live. Lenacapavir’s breakthrough pricing of approximately 40 dollars per person per year for low and middle income countries, announced at the September 2025 Clinton Global Initiative meeting, transformed it from a theoretical option to a practical one, but the Global Fund and PEPFAR commitments that underpin that access are themselves subject to the kind of donor instability that has already disrupted services elsewhere. Generic versions of lenacapavir are not expected before 2027, meaning the current rollout depends entirely on supply from Gilead Sciences at the negotiated originator price. Health analysts writing in the Nigerian Independent newspaper described the arrival as a strategic expansion of prevention options with genuine potential to transform the country’s HIV response, but emphasised that without deliberate strategies to reach vulnerable populations — particularly in rural communities and among groups disproportionately affected — lenacapavir risks becoming another symbol of progress that benefits only a fraction of those in need.
